Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Steven D. Gore, MD, Bart L. Scott, MD, Christopher R. Cogle, MD, Thomas Boyd, MD, Paul Conkling, Joel Hetzer, PhD, Qian Dong, MS, Keshava Kumar, PhD, Stacey M. Ukrainskyj, BSN, Barry S. Skikne, MD

Blood (2016) 128 (22): 905.

https://doi.org/10.1182/blood.V128.22.905.905

Published: 2016

Journal Articles

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, Lionel Ades, MD PhD, Abderrahmane Laadem, MD, Bond Vo, PharmD, Thomas Prebet, MD PhD, Aspasia Stamatoullas, MD, Thomas Boyd, MD, Jacques Delaunay, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Odile Beyne-Rauzy, MD PhD, Jun Zou, MS, Kenneth Attie, MD, Matthew L. Sherman, MD, Pierre Fenaux, MD PhD, Alan F. List, MD

Blood (2014) 124 (21): 3251.

https://doi.org/10.1182/blood.V124.21.3251.3251

Published: 2014

Journal Articles

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, MD, PhD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Ronald L. Dubowy, MD, Steven E. Coutre, MD

Blood (2013) 122 (21): 2878.

https://doi.org/10.1182/blood.V122.21.2878.2878

Published: 2013

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, Sven De Vos, MD, PhD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, Nathan Fowler, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Leanne M. Holes, Roger Dansey, MD, Thomas M. Jahn, MD, PhD, Steven E. Coutre, MD

Blood (2013) 122 (21): 4180.

https://doi.org/10.1182/blood.V122.21.4180.4180

Published: 2013

Journal Articles

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, MB ChB, PhD, Tadeusz Robak, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Thomas Boyd, MD, Marco Montillo, MD, Astrid McKeown, PhD, Jodi L Carey, RN, BSN, Ira V Gupta, MD, Chai-Ni Chang, MS, Steen Lisby, MD, DMSc, Fritz Offner, MD

Blood (2013) 122 (21): 528.

https://doi.org/10.1182/blood.V122.21.528.528

Published: 2013

Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Jeff Sharman, MD, Sven de Vos, MD, PhD, John P. Leonard, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Jaqueline C. Barrientos, MD, Nina D. Wagner-Johnston, Thomas Boyd, MD, Nathan H. Fowler, MD, Leanne Holes, Brian Lannutti, David Johnson, Thomas M. Jahn, Langdon L Miller

Blood (2011) 118 (21): 1787.

https://doi.org/10.1182/blood.V118.21.1787.1787

Published: 2011

Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

Sven de Vos, MD, PhD, Marshall T. Schreeder, Ian W. Flinn, MD, PhD, Steven E. Coutre, MD, John P. Leonard, MD, Nina D. Wagner-Johnston, Nathan H. Fowler, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Thomas Boyd, MD, Jeff Sharman, MD, Leanne Holes, Brian Lannutti, Dave M. Johnson, Thomas M. Jahn, Langdon L Miller

Blood (2011) 118 (21): 2699.

https://doi.org/10.1182/blood.V118.21.2699.2699

Published: 2011

Journal Articles

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Nathan Fowler, MD, Jeff Porte Sharman, MD, Sonali M Smith, MD, Thomas Boyd, MD, Barbara Grant, MD, Kathryn S. Kolibaba, MD, Richard R. Furman, MD, Joseph Buggy, David Loury, PhD, Ahmed Hamdy, Ranjana Advani, MD

Blood (2010) 116 (21): 964.

https://doi.org/10.1182/blood.V116.21.964.964

Published: 2010

Journal Articles

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Lihua E Budde, MD., PhD, Andrei Shustov, MD, John M. Pagel, MD, PhD, Ted Gooley, PhD, George Oliviera, MD, Tara Chen, PharmD, Michelle Zhang, MD, Thomas A. Warr, MD, Thomas Boyd, MD, Oliver W. Press, MD, PhD, Ajay K Gopal, MD

Blood (2010) 116 (21): 2790.

https://doi.org/10.1182/blood.V116.21.2790.2790

Published: 2010

Journal Articles

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Nicholas Di Bella, Raymond Taetle, Kathryn Kolibaba, Thomas Boyd, Robert Raju, David Barrera, Ernest W. Cochran, Jr, Philip Y. Dien, Roger Lyons, Peter J. Schlegel, Svetislava J. Vukelja, Julie Boston, Kristi A. Boehm, Yunfei Wang, Lina Asmar

Blood (2010) 115 (3): 475–480.

https://doi.org/10.1182/blood-2009-08-233155

Published: 2010

NARROW

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only